Aquestive Therapeutics Stock Probability of Future Stock Price Finishing Over 4.51

AQST Stock  USD 4.56  0.05  1.11%   
Aquestive Therapeutics' future price is the expected price of Aquestive Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Aquestive Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Aquestive Therapeutics Backtesting, Aquestive Therapeutics Valuation, Aquestive Therapeutics Correlation, Aquestive Therapeutics Hype Analysis, Aquestive Therapeutics Volatility, Aquestive Therapeutics History as well as Aquestive Therapeutics Performance.
For more information on how to buy Aquestive Stock please use our How to Invest in Aquestive Therapeutics guide.
  
At this time, Aquestive Therapeutics' Price To Sales Ratio is comparatively stable compared to the past year. Price Earnings To Growth Ratio is likely to gain to 0.18 in 2024, despite the fact that Price To Operating Cash Flows Ratio is likely to grow to (18.42). Please specify Aquestive Therapeutics' target price for which you would like Aquestive Therapeutics odds to be computed.

Aquestive Therapeutics Target Price Odds to finish over 4.51

The tendency of Aquestive Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 4.51  in 90 days
 4.56 90 days 4.51 
about 84.13
Based on a normal probability distribution, the odds of Aquestive Therapeutics to stay above $ 4.51  in 90 days from now is about 84.13 (This Aquestive Therapeutics probability density function shows the probability of Aquestive Stock to fall within a particular range of prices over 90 days) . Probability of Aquestive Therapeutics price to stay between $ 4.51  and its current price of $4.56 at the end of the 90-day period is under 4.
Given the investment horizon of 90 days the stock has the beta coefficient of 1.78 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Aquestive Therapeutics will likely underperform. Additionally Aquestive Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Aquestive Therapeutics Price Density   
       Price  

Predictive Modules for Aquestive Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aquestive Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aquestive Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.394.558.71
Details
Intrinsic
Valuation
LowRealHigh
0.915.079.23
Details
Naive
Forecast
LowNextHigh
0.284.438.59
Details
8 Analysts
Consensus
LowTargetHigh
5.616.176.85
Details

Aquestive Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Aquestive Therapeutics is not an exception. The market had few large corrections towards the Aquestive Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aquestive Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aquestive Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.06
β
Beta against Dow Jones1.78
σ
Overall volatility
0.35
Ir
Information ratio 0.01

Aquestive Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aquestive Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aquestive Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Aquestive Therapeutics had very high historical volatility over the last 90 days
Aquestive Therapeutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 50.58 M. Net Loss for the year was (7.87 M) with profit before overhead, payroll, taxes, and interest of 28.29 M.
Aquestive Therapeutics currently holds about 17.7 M in cash with (6.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc

Aquestive Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aquestive Stock often depends not only on the future outlook of the current and potential Aquestive Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aquestive Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding61.3 M
Cash And Short Term Investments23.9 M

Aquestive Therapeutics Technical Analysis

Aquestive Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Aquestive Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aquestive Therapeutics. In general, you should focus on analyzing Aquestive Stock price patterns and their correlations with different microeconomic environments and drivers.

Aquestive Therapeutics Predictive Forecast Models

Aquestive Therapeutics' time-series forecasting models is one of many Aquestive Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aquestive Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Aquestive Therapeutics

Checking the ongoing alerts about Aquestive Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aquestive Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aquestive Therapeutics had very high historical volatility over the last 90 days
Aquestive Therapeutics has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported the previous year's revenue of 50.58 M. Net Loss for the year was (7.87 M) with profit before overhead, payroll, taxes, and interest of 28.29 M.
Aquestive Therapeutics currently holds about 17.7 M in cash with (6.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Latest headline from gurufocus.com: ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc

Additional Tools for Aquestive Stock Analysis

When running Aquestive Therapeutics' price analysis, check to measure Aquestive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aquestive Therapeutics is operating at the current time. Most of Aquestive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aquestive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aquestive Therapeutics' price. Additionally, you may evaluate how the addition of Aquestive Therapeutics to your portfolios can decrease your overall portfolio volatility.